China is now the world’s second largest pharmaceutical market, trailing only the United States. Even with that size, its companies cannot ignore large Western and developing markets. This paper examines Chinese biopharmaceutical companies with global growth aspirations – their typical strengths and weaknesses; how to leverage their “Asia advantage” in implementing global growth strategies; market access issues for Europe, the United States and Japan; and other success factors for Chinese companies to become global biopharma powerhouses.
- Geoff Garabedian, Senior Vice President and Managing Director, Quintiles Advisory Service
- Christoph Schnorr, MD, Vice President, Quintiles Advisory Services
- Ling Zhen, JD, MBA, General Manager and Head of Greater China, Quintiles